Your browser doesn't support javascript.
loading
Targeting GSTP1 as Therapeutic Strategy against Lung Adenocarcinoma Stemness and Resistance to Tyrosine Kinase Inhibitors.
Wang, Si-Qi; Chen, Jun-Jiang; Jiang, Yuchen; Lei, Zi-Ning; Ruan, Ye Chun; Pan, Yihang; Yam, Judy Wai Ping; Wong, Maria Pik; Xiao, Zhi-Jie.
Afiliação
  • Wang SQ; State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China.
  • Chen JJ; Department of Pathology, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, 999077, China.
  • Jiang Y; Institute for Stem Cell and Regenerative Medicine, Chinese Academy of Sciences, Beijing, 100101, China.
  • Lei ZN; Bejing Institute for Stem Cell and Regenerative Medicine, Beijing, 100101, China.
  • Ruan YC; Department of Physiology, School of Medicine, Jinan University, Guangzhou, 510000, China.
  • Pan Y; Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong SAR, 999077, China.
  • Yam JWP; Scientific Research Centre, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518000, China.
  • Wong MP; Scientific Research Centre, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518000, China.
  • Xiao ZJ; Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong SAR, 999077, China.
Adv Sci (Weinh) ; 10(7): e2205262, 2023 03.
Article em En | MEDLINE | ID: mdl-36709476
ABSTRACT
Glutathione S-transferase pi (GSTP1), a phase II detoxification enzyme, is known to be overexpressed and mediates chemotherapeutic resistance in lung cancer. However, whether GSTP1 supports cancer stem cells (CSCs) and the underlying mechanisms in lung adenocarcinoma (LUAD) remain largely unknown. This study unveiled that GSTP1 is upregulated in lung CSCs and supports tumor self-renewal, metastasis, and resistance to targeted tyrosine kinase inhibitors of LUAD both in vitro and in vivo. Mechanistically, CaMK2A (calcium/calmodulin-dependent protein kinase 2 isoform A)/NRF2 (nuclear factor erythroid 2-related factor 2)/GSTP1 is uncovered as a regulatory axis under hypoxia. CaMK2A increased GSTP1 expression through phosphorylating the Sersine558 residue of NRF2 and promoting its nuclear translocation, a novel mechanism for NRF2 activation apart from conventional oxidization-dependent activation. Upregulation of GSTP1 in turn suppressed reactive oxygen species levels and supported CSC phenotypes. Clinically, GSTP1 analyzed by immunohistochemistry is upregulated in a proportion of LUAD and serves as a prognostic marker for survival. Using patient-derived organoids from an ALK-translocated LUAD, the therapeutic potential of a specific GSTP1 inhibitor ezatiostat in combination treatment with the ALK inhibitor crizotinib is demonstrated. This study demonstrates GSTP1 to be a promising therapeutic target for long-term control of LUAD through targeting CSCs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma de Pulmão / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Adv Sci (Weinh) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma de Pulmão / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Adv Sci (Weinh) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China